Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS)

Corvus Pharmaceuticals, Inc. (CRVS) is a clinical-stage biopharmaceutical company that operates in the biotechnology industry. With a focus on the development of immune modulator product candidates, the company aims to treat a range of diseases including solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Corvus Pharmaceuticals' lead product candidate, soquelitinib, is a selective, covalent inhibitor of ITK, an enzyme that plays a key role in T cell signaling and differentiation.

Corvus Pharmaceuticals' main business activities revolve around the development of novel, targeted therapies for the treatment of various diseases. The company's operations span across the United States, Australia, China, and South Korea, where it conducts clinical trials for its product candidates. Corvus Pharmaceuticals' expertise in immunology and oncology has enabled it to develop a diverse and versatile product pipeline.

The company generates revenue through the development and commercialization of its product candidates. Its primary products include soquelitinib, ciforadenant, and mupadolimab, which are being evaluated in clinical trials. Soquelitinib is an orally bioavailable compound that has demonstrated anti-tumor activity in preclinical studies and is currently being evaluated in a Phase 1/1b clinical trial in patients with advanced, refractory T cell lymphomas. Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine, which is designed to disable a tumor's ability to subvert attack by the immune system. Mupadolimab is a humanized monoclonal antibody that is designed to react with a specific site on CD73, an enzyme that is involved in the regulation of immune responses.

Corvus Pharmaceuticals is well-positioned within the industry, boasting a strong management team with a track record of developing successful biotechnology companies. Its competitive advantages lie in its expertise in immunology and oncology, its diverse and versatile product pipeline, and its ability to develop novel, targeted therapies.

The company's customers include the Kidney Cancer Research Consortium, which is collaborating with Corvus Pharmaceuticals on the development of ciforadenant. Corvus Pharmaceuticals also has a number of partners, including Angel Pharmaceuticals Co. Ltd., which is developing mupadolimab in China.

In terms of brand names, Corvus Pharmaceuticals has a number of product candidates in its pipeline, including soquelitinib, ciforadenant, and mupadolimab. The company also has a license agreement with Vernalis, which grants Corvus Pharmaceuticals an exclusive, worldwide license under certain patent rights and know-how to develop and commercialize products containing certain adenosine receptor antagonists, including ciforadenant. Additionally, Corvus Pharmaceuticals has a license agreement with Scripps, which grants the company a non-exclusive, world-wide license under certain know-how and technology related to a mouse hybridoma clone expressing an anti-human CD73 antibody, and to progeny, mutants or unmodified derivatives of such hybridoma and any antibodies expressed by such hybridoma.